GOAL
The overall goal of this educational activity will be to provide primary care physicians and advanced practice nurses who treat patients with fibromyalgia syndrome (FMS) the best available scientific evidence and therapeutic strategies so that they can deliver successful treatments to their patients with FMS.
OVERVIEW
Fibromyalgia is a widespread, chronic pain disorder that includes a multifaceted constellation of somatic and emotional symptoms. Although diagnosis and treatment can be challenging with many barriers to successful management, an increasing understanding of the mechanisms of central pain pathways now provides novel therapeutic opportunities. This activity will focus on key questions that have surrounded the diagnosis and treatments of fibromyalgia: (1) Is it science or somatic?; (2) How do you overcome barriers to effective treatment?; and (3) How do you modify pain response?
Clinicians who treat patients with fibromyalgia need to be familiar with the most current pharmacologic and nonpharmacologic methods available. Treating these patients can be very time-consuming because this syndrome appears to fall outside of the umbrella of typical immuno-inflammatory diseases. Through dynamic presentations and interactive cases, this CME activity is designed to provide you with current information and skills to improve care.
TARGET AUDIENCE
This activity is designed to meet the needs of primary care physicians and advanced practice nurses who treat patients with FMS. No prerequisites required.
CME INFORMATION
Accreditation Statement — The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement — The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
After reviewing this online activity, participants may receive credit by completing the CME test, evaluation, and receiving a score of 70% or higher.
The estimated time to complete this activity: 1.5 hours.
Release date: March 15, 2010. Expiration date: March 15, 2012.
Activity Format — Archived webcast of a national symposium series.
Fee Information — There is no fee for this educational activity.
Full Disclosure Policy Affecting CME Activities —As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Participating Faculty reported the following:
Steven Cohen, MD (Chair)
Associate Professor of Anesthesiology
Johns Hopkins University
Director of Medical Education for Pain Management Division
Walter Reed Army Medical Center
Director of Pain Research
Baltimore, Maryland
Dr Cohen reports having no relationships with commercial interests related to this activity.
Daniel Clauw, MD
Professor of Anesthesiology and Medicine
University of Michigan
Ann Arbor, Michigan
Dr Clauw reports serving as the principal investigator on grants from Forest Laboratories and Pfizer Inc; and serving as a consultant for AstraZeneca, Eli Lilly and Company, Pierre Fabre, and UCB, Inc.
Howard Smith, MD
Associate Professor of Anesthesiology, Internal Medicine, and Physical Rehabilitation & Medicine
Academic Director of Pain Management
Albany Medical College
Department of Anesthesiology
Albany, New York
Dr Smith reports serving on the speakers’ bureau for Cypress Pharmaceutical, Inc and Forest Laboratories.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grant, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
Off-Label Product Discussion
The audience is advised that presentations in this CME activity contain reference(s) to unlabeled or unapproved uses of drugs or devices:
Dr Clauw—γ-hydroxybutyrate, selective serotonin reuptake inhibitors, and tricyclic antidepressants.
All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.
Disclaimer Statement
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This archived webcast is produced for educational purposes only. Use of The Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.
Internet CME Policy
The Office of Continuing Medical Education (CME) at The Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University School of Medicine CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at The Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet-based activity. Your information will never be given to anyone outside of The Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.
| Please complete the pre-test, listen to the following presentations, and complete the post-test and evaluation to receive CME credit for this activity. Pre-Test
Fibromyalgia Syndrome: Science or Somatic?
Howard S. Smith, MD
Overcoming Obstacles: Barriers to Care in Fibromyalgia Treatment
Steven P. Cohen, MD
Targeting Neurotransmitters: Modulating Pain Response
Daniel Clauw, MD
Post-Test |
|
|
